Cite
HARVARD Citation
Wong, C. et al. (2022). Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study. Postgraduate medical journal. 98 (1163), pp. 666-669. [Online].